



MSD Pipeline

Q3 2024 Reflecting Pipeline to
Aug 2, 2024

Lead-in language

The chart below reflects the company's research pipeline as of **Aug 2, 2024**. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1, additional indications in the same therapeutic area (other than with respect to cancer and certain other indications) and additional claims, line extensions or formulations for in-line products are not shown.

MSD pipeline as of Aug 2, 2024

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda
3. Being developed as monotherapy and/or in combination with Keytruda

▶ Moved forward since last pipeline update.

| Phase 2 | Phase 2 | Phase 2 | Phase 2 | Phase 2 |
|------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| ▶ Cancer Gastric HNSCC Melanoma patritumab deruxtecan MK-1022 ¹ | Cancer NSCLC quavonlimab MK-1308 ² | Cancer CRC quavonlimab + pembrolizumab MK-1308A | Thrombosis MK-2060 | Heme zilovertamab vedotin MK-2140 |
| ▶ Cancer Bladder CRC Endometrial HNSCC ifinatumab deruxtecan MK-2400 ¹ | ▶ Cancer Biliary CRC Neoplasm Malignant Pancreatic sacituzumab tirumotecan MK-2870 ^{1,3} | ▶ Diabetic macular edema Restoret™ MK-3000 | Cancer Advanced solid tumors Prostate KEYTRUDA® MK-3475 | Cancer Cutaneous Squamous Cell pembrolizumab + hyaluronidase subcutaneous MK-3475A |
| Cancer NSCLC favezelimab MK-4280 ² | Cancer Bladder Cutaneous Squamous Cell Endometrial Esophageal Melanoma RCC favezelimab + pembrolizumab MK-4280A | PH-COPD MK-5475 | Cancer Neoplasm Malignant boserolimab MK-5890 ² | Cancer Ovarian raludotatug deruxtecan MK-5909 ¹ |

MSD pipeline as of Aug 2, 2024

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda
3. Being developed as monotherapy and/or in combination with Keytruda
4. On FDA clinical hold
5. On partial clinical hold for higher doses than those used in current clinical trials
6. Phase 2b development costs are being co-funded

▶ Moved forward since last pipeline update.

| Phase 2 | Phase 2 | Phase 2 | Phase 2 | Phase 2 |
|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| NASH efinopegdutide MK-6024 | Vitiligo MK-6194 | Cancer Endometrial Esophageal HCC Prostate Rare cancers WELIREG™ MK-6482 ³ | Cancer Advanced solid tumors LYNPARZA® MK-7339 ^{1,3} | Cancer Bladder CRC Endometrial Melanoma Ovarian Prostate RCC vibostolimab + pembrolizumab MK-7684A |
| Cancer HNSCC LENVIMA® MK-7902 ^{1,2} | Pulmonary Hypertension due to Left Heart Disease WINREVAIR™ MK-7962 | Schizophrenia MK-8189 ⁶ | HIV-1 prevention MK-8527 | HIV-1 Infection islatravir+MK-8507 MK-8591B ⁴ |
| HIV-1 Infection islatravir+lenacapavir MK-8591D ^{1,5} | Dengue fever virus Vaccine V181 | Cancer Bladder Cutaneous Squamous Cell Carcinoma RCC V940 ^{1,2} | | |

MSD pipeline as of Aug 2, 2024

1. Being developed in a collaboration.
2. Being developed in combination with Keytruda
3. Being developed as monotherapy and/or in combination with Keytruda
4. On partial clinical hold for higher doses than those used in current clinical trials
5. Available in the U.S. under Emergency Use Authorization

▶ Moved forward since last pipeline update.

| Phase 3 | Phase 3 | Phase 3 | Phase 3 |
|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|
| Hypercholesterolemia MK-0616 | Cancer NSCLC patritumab deruxtecan MK-1022 ¹ (EU) | Cancer Heme nemtabrutinib MK-1026 | Cancer NSCLC KRAS G12C MK-1084 |
| Cancer RCC quavonlimab + pembrolizumab MK-1308A | Respiratory syncytial virus clesrovimab MK-1654 | Cancer SCLC ifinatumab deruxtecan MK-2400 ¹ | Cancer Breast Cervical Gastric Endometrial NSCLC sacituzumab tirumotecan MK-2870 ^{1,3} |
| Cancer Cutaneous Squamous Cell Carcinoma (EU) Hepatocellular (EU) Ovarian SCLC KEYTRUDA [®] MK-3475 | Cancer NSCLC pembrolizumab + hyaluronidase subcutaneous MK-3475A | Cancer Myeloproliferative Disorders bomedemstat MK-3543 | Cancer CRC Heme favezelimab + pembrolizumab MK-4280A |
| Anti-Viral COVID-19 LAGEVRIO [®] MK-4482 ^{1,5} (US) | Cancer Prostate opevesostat MK-5684 ¹ | Ulcerative Colitis tulisokibart MK-7240 | Cancer NSCLC SCLC LYNPARZA [®] MK-7339 ^{1,2} |
| Cancer NSCLC SCLC vibostolimab + pembrolizumab MK-7684A | Cancer Esophageal Gastric LENVIMA [®] MK-7902 ^{1,2} | HIV-1 infection doravirine + islatravir MK-8591A ⁴ | Cancer Melanoma NSCLC V940 ^{1,2} |

MSD pipeline as of Aug 2, 2024

1. Being developed in a collaboration
2. In June 2024, FDA issued a CRL for the BLA for patritumab deruxtecan. MSD is working with Daiichi Sankyo to address FDA feedback.
3. In Dec 2023, FDA issued a CRL for the NDA for gefapixant. MSD is reviewing the feedback to determine next steps.

▶ Moved forward since last pipeline update.

| New Molecular Entities Under Review | New Molecular Entities Under Review |
|-------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------|
| Previously Treated Locally Advanced or Metastatic EGFR-Mutated NSCLC (HERTHENA-Lung01) patritumab deruxtecan MK-1022 ^{1,2} (US) | von Hippel-Lindau (VHL) disease (LITESPARK-004) WELIREG® MK-6482 (EU) |
| Cough gefapixant MK-7264 (US ³) | Pulmonary Arterial Hypertension (STELLAR) WINREVAIR™ MK-7962 (EU) |
| Pneumococcal Vaccine Adult CAPVAXIVE™ V116 (EU) | |

| Certain Supplemental Filings Under Review | Certain Supplemental Filings Under Review | Certain Supplemental Filings Under Review |
|-------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------|
| High-Risk Locally Advanced Cervical Cancer (KNA18) KEYTRUDA® MK-3475 (EU, JPN) | Primary Advanced or Recurrent Endometrial Carcinoma (KN868) KEYTRUDA® MK-3475 (EU, JPN) | 1L Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (KN483) KEYTRUDA® MK-3475 (US, EU, JPN) |
| Resectable Stage II, IIIA or IIIB NSCLC (KN671) KEYTRUDA® MK-3475 (JPN) | Previously Treated Advanced Renal Cell Carcinoma (LITESPARK-005) WELIREG® MK-6482 (EU, JPN) | 1L Locally Advanced or Metastatic Urothelial Cancer (KNA39) KEYTRUDA® MK-3475 (EU, JPN) |

1. Approvals obtained within the last 3 months.
 2. Being developed in a collaboration
- ▶ Moved forward since last pipeline update.

MSD pipeline as of Aug 2, 2024

| New Molecular Entities Approvals ¹ | Certain Supplemental Approvals ¹ | Certain Supplemental Approvals ¹ |
|-------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
| <p>▶ Pneumococcal Vaccine Adult CAPVAXIVE™ V116 (US)</p> | <p>▶ 1L Locally Advanced Unresectable or Metastatic Biliary Tract Cancer (KN966) KEYTRUDA® MK-3475 (JPN)</p> | <p>▶ Primary Advanced or Recurrent Endometrial Carcinoma (KN868) KEYTRUDA® MK-3475 (US)</p> |
| | <p>▶ Metastatic HER2+ Gastric Cancer (KN811) KEYTRUDA® MK-3475 (CHN)</p> | <p>▶ 1L HER2 negative Locally Advanced Unresectable or Metastatic Gastric Cancer (KN859) KEYTRUDA® MK-3475 (JPN)</p> |
| | <p>▶ Prophylaxis of CMV in organ transplant patients PREVYMIS® MK-8228 (JPN)</p> | |

Forward-looking statement

This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

No duty to update

The information contained in the presentation set forth below was current as of Aug 2, 2024. While this presentation remains on the company's website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not rely upon the information as current or accurate after Aug 2, 2024.

The chart reflects the MSD research pipeline as of Aug 2, 2024.

Candidates shown in Phase 3 include specific products. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism in a given therapeutic area. Phase 1 candidates are not shown.